Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

A Mutation in Histone H2B Represents a New Class of Oncogenic Driver.

Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, Huang X, Ghosh RP, Grzybowski AT, Yu T, Zhang Q, Riva A, Lele TP, Schatz GC, Kelleher NL, Ruthenburg AJ, Liphardt J, Licht JD.

Cancer Discov. 2019 Jul 23. doi: 10.1158/2159-8290.CD-19-0393. [Epub ahead of print]

PMID:
31337617
2.

Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine.

Vaquero M, Cuesta S, Anerillas C, Altés G, Ribera J, Basson MA, Licht JD, Egea J, Encinas M.

J Am Soc Nephrol. 2019 Aug;30(8):1398-1411. doi: 10.1681/ASN.2018111085. Epub 2019 Jul 12.

PMID:
31300484
3.

Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.

Huang X, LeDuc RD, Fornelli L, Schunter AJ, Bennett RL, Kelleher NL, Licht JD.

J Biol Chem. 2019 Aug 16;294(33):12459-12471. doi: 10.1074/jbc.RA118.006159. Epub 2019 Jun 27.

PMID:
31248990
4.

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM.

Clin Cancer Res. 2019 Sep 15;25(18):5686-5701. doi: 10.1158/1078-0432.CCR-18-3382. Epub 2019 Jun 21.

PMID:
31227503
5.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM.

Cancer Res. 2019 Jun 1;79(11):2947-2961. doi: 10.1158/0008-5472.CAN-19-0040. Epub 2019 Apr 15.

PMID:
30987999
6.

Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.

Alzrigat M, Jernberg-Wiklund H, Licht JD.

Epigenomes. 2018 Sep;2(3). pii: 16. doi: 10.3390/epigenomes2030016. Epub 2018 Sep 3.

7.

Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemia-reperfusion injury.

Alakoski T, Ulvila J, Yrjölä R, Vainio L, Magga J, Szabo Z, Licht JD, Kerkelä R.

Basic Res Cardiol. 2019 Jan 11;114(2):7. doi: 10.1007/s00395-018-0713-y.

8.

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.

Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J.

Cell Rep. 2018 Dec 4;25(10):2808-2820.e4. doi: 10.1016/j.celrep.2018.11.035.

9.

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD Jr, Bennett RL, Kelleher NL, Licht JD.

Oncogene. 2019 Jan;38(5):671-686. doi: 10.1038/s41388-018-0474-y. Epub 2018 Aug 31.

10.
11.

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.

Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D.

Blood. 2018 Jul 26;132(4):423-434. doi: 10.1182/blood-2017-10-811760. Epub 2018 May 29.

12.

A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.

Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, Licht JD, Collings CK, Bartom E, Theodorescu D, Shilatifard A, Meeks JJ.

Oncogene. 2018 Apr;37(14):1911-1925. doi: 10.1038/s41388-017-0099-6. Epub 2018 Jan 25.

13.

SETD2: a complex role in blood malignancy.

Licht JD.

Blood. 2017 Dec 14;130(24):2576-2578. doi: 10.1182/blood-2017-10-811927. No abstract available.

14.

Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogen-mediated changes in cell cycle regulatory circuits.

Yang X, Gong Y, He Q, Licht JD, Liaw L, Friesel RE.

J Cell Biochem. 2018 Apr;119(4):3267-3279. doi: 10.1002/jcb.26486. Epub 2017 Dec 26.

15.

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.

Ezponda T, Dupéré-Richer D, Will CM, Small EC, Varghese N, Patel T, Nabet B, Popovic R, Oyer J, Bulic M, Zheng Y, Huang X, Shah MY, Maji S, Riva A, Occhionorelli M, Tonon G, Kelleher N, Keats J, Licht JD.

Cell Rep. 2017 Oct 17;21(3):628-640. doi: 10.1016/j.celrep.2017.09.078.

16.

Targeting Epigenetics in Cancer.

Bennett RL, Licht JD.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207. doi: 10.1146/annurev-pharmtox-010716-105106. Epub 2017 Oct 6. Review.

17.

The nucleus is irreversibly shaped by motion of cell boundaries in cancer and non-cancer cells.

Tocco VJ, Li Y, Christopher KG, Matthews JH, Aggarwal V, Paschall L, Luesch H, Licht JD, Dickinson RB, Lele TP.

J Cell Physiol. 2018 Feb;233(2):1446-1454. doi: 10.1002/jcp.26031. Epub 2017 Jul 31.

18.

Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.

Dupéré-Richer D, Licht JD.

Curr Opin Hematol. 2017 Jul;24(4):336-344. doi: 10.1097/MOH.0000000000000358. Review.

19.

The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Bennett RL, Swaroop A, Troche C, Licht JD.

Cold Spring Harb Perspect Med. 2017 Jun 1;7(6). pii: a026708. doi: 10.1101/cshperspect.a026708. Review.

20.

FQI1: a transcription-methylation switch for cancer.

Guryanova OA, Licht JD.

Oncotarget. 2017 Feb 21;8(8):12536-12537. doi: 10.18632/oncotarget.15087. No abstract available.

21.

Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.

Mahajan N, Wu HJ, Bennett RL, Troche C, Licht JD, Weber JD, Maggi LB Jr, Tomasson MH.

FASEB J. 2017 Feb;31(2):482-490. doi: 10.1096/fj.201600654R. Epub 2016 Oct 24.

22.

Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.

Schauwecker SM, Kim JJ, Licht JD, Clevenger CV.

J Biol Chem. 2017 Feb 10;292(6):2237-2254. doi: 10.1074/jbc.M116.764233. Epub 2016 Dec 29.

23.

Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis.

Arcipowski KM, Bulic M, Gurbuxani S, Licht JD.

PLoS One. 2016 Sep 9;11(9):e0162515. doi: 10.1371/journal.pone.0162515. eCollection 2016.

24.

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.

Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, Hamline MY, Gascoyne RD, Levine RL, Abdel-Wahab O, Licht JD, Shaknovich R, Elemento O, Bardwell VJ, Melnick AM.

Cancer Cell. 2016 Aug 8;30(2):197-213. doi: 10.1016/j.ccell.2016.07.006.

25.

H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Nichol JN, Dupéré-Richer D, Ezponda T, Licht JD, Miller WH Jr.

Adv Cancer Res. 2016;131:59-95. doi: 10.1016/bs.acr.2016.05.001. Epub 2016 Jun 17. Review.

26.

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, Calvo-Vidal MN, Nichol JN, Guilbert C, Plourde D, Klein Oros K, Nielsen TH, Ezponda T, Licht JD, Johnson NA, Assouline S, Cerchietti L, Miller WH Jr, Mann KK.

Leuk Lymphoma. 2017 Jan;58(1):218-221. Epub 2016 May 17. No abstract available.

PMID:
27185211
27.

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.

Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, Ezponda T, Small EC, Will C, Phillip MP, Neri P, Bahlis NJ, Wirtz D, Licht JD.

Oncogene. 2016 Nov 10;35(45):5905-5915. doi: 10.1038/onc.2016.116. Epub 2016 Apr 25.

28.

Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases.

McConnell MJ, Durand L, Langley E, Coste-Sarguet L, Zelent A, Chomienne C, Kouzarides T, Licht JD, Guidez F.

Epigenetics Chromatin. 2015 Sep 24;8:38. doi: 10.1186/s13072-015-0030-8. eCollection 2015.

29.

DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension.

Licht JD.

Cell. 2015 Aug 27;162(5):938-9. doi: 10.1016/j.cell.2015.08.005.

30.

Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.

Nabet B, Ó Broin P, Reyes JM, Shieh K, Lin CY, Will CM, Popovic R, Ezponda T, Bradner JE, Golden AA, Licht JD.

Cell Rep. 2015 Aug 25;12(8):1300-13. doi: 10.1016/j.celrep.2015.06.078. Epub 2015 Aug 13.

31.

Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.

Zheng Y, Fornelli L, Compton PD, Sharma S, Canterbury J, Mullen C, Zabrouskov V, Fellers RT, Thomas PM, Licht JD, Senko MW, Kelleher NL.

Mol Cell Proteomics. 2016 Mar;15(3):776-90. doi: 10.1074/mcp.M115.053819. Epub 2015 Aug 13.

32.

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.

Kumar K, Raza SS, Knab LM, Chow CR, Kwok B, Bentrem DJ, Popovic R, Ebine K, Licht JD, Munshi HG.

Sci Rep. 2015 Mar 25;5:9489. doi: 10.1038/srep09489.

33.

Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.

Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN, Licht JD, Chen YH.

Leuk Lymphoma. 2015;56(10):2895-901. doi: 10.3109/10428194.2015.1006220. Epub 2015 Mar 8.

PMID:
25651430
34.

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.

Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL.

Cell Rep. 2014 Dec 11;9(5):1841-1855. doi: 10.1016/j.celrep.2014.11.004. Epub 2014 Dec 4.

35.

Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.

Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC, Hua Y, Bulic M, Jiang Y, Carrara M, Calogero RA, Kath WL, Kelleher NL, Wang JP, Elemento O, Licht JD.

PLoS Genet. 2014 Sep 4;10(9):e1004566. doi: 10.1371/journal.pgen.1004566. eCollection 2014 Sep.

36.

Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.

Ezponda T, Licht JD.

Clin Cancer Res. 2014 Oct 1;20(19):5001-8. doi: 10.1158/1078-0432.CCR-13-2499. Epub 2014 Jul 1. Review.

37.

Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity.

Small EC, Xi L, Wang JP, Widom J, Licht JD.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):E2462-71. doi: 10.1073/pnas.1400517111. Epub 2014 Jun 2.

38.

Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.

Choi WI, Yoon JH, Kim MY, Koh DI, Licht JD, Kim K, Hur MW.

J Biol Chem. 2014 Jul 4;289(27):18641-56. doi: 10.1074/jbc.M113.538777. Epub 2014 May 12.

39.

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.

Licht JD, Shortt J, Johnstone R.

Cancer Cell. 2014 Jan 13;25(1):9-11. doi: 10.1016/j.ccr.2013.12.019.

40.

Spry1 and Spry2 are necessary for eyelid closure.

Kuracha MR, Siefker E, Licht JD, Govindarajan V.

Dev Biol. 2013 Nov 15;383(2):227-38. doi: 10.1016/j.ydbio.2013.09.014. Epub 2013 Sep 17.

41.

Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.

Frankfurt O, Licht JD.

Clin Cancer Res. 2013 Nov 1;19(21):5828-34. doi: 10.1158/1078-0432.CCR-13-0258. Epub 2013 Aug 9. Review.

42.

Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.

Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, Levine RL, Ferrando A, Mackerell AD Jr, Kelleher NL, Licht JD, Popovic R.

Leukemia. 2014 Jan;28(1):198-201. doi: 10.1038/leu.2013.204. Epub 2013 Jul 4. No abstract available.

43.

Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.

Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC.

J Biol Chem. 2013 Aug 16;288(33):23814-22. doi: 10.1074/jbc.M113.476192. Epub 2013 Jun 28.

44.

The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.

Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ, Chandel NS.

Mol Cell. 2013 Jul 25;51(2):236-48. doi: 10.1016/j.molcel.2013.05.003. Epub 2013 Jun 6. Erratum in: Mol Cell. 2013 Jul 25;51(2):273.

45.

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM.

Cancer Cell. 2013 May 13;23(5):677-92. doi: 10.1016/j.ccr.2013.04.011.

46.

A physical sciences network characterization of non-tumorigenic and metastatic cells.

Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH.

Sci Rep. 2013;3:1449. doi: 10.1038/srep01449.

47.

Epigenetic therapy of hematological malignancies: where are we now?

Popovic R, Shah MY, Licht JD.

Ther Adv Hematol. 2013 Apr;4(2):81-91. doi: 10.1177/2040620712466864.

48.

Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis.

Petruccelli LA, Pettersson F, Del Rincón SV, Guilbert C, Licht JD, Miller WH Jr.

Mol Cancer Ther. 2013 Aug;12(8):1591-604. doi: 10.1158/1535-7163.MCT-12-1039. Epub 2013 Mar 27.

49.

Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling.

Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang CR, Schumacker PT, Licht JD, Perlman H, Bryce PJ, Chandel NS.

Immunity. 2013 Feb 21;38(2):225-36. doi: 10.1016/j.immuni.2012.10.020. Epub 2013 Feb 15.

50.

Regulation of CD4⁺ and CD8⁺ effector responses by Sprouty-1.

Collins S, Waickman A, Basson A, Kupfer A, Licht JD, Horton MR, Powell JD.

PLoS One. 2012;7(11):e49801. doi: 10.1371/journal.pone.0049801. Epub 2012 Nov 15.

Supplemental Content

Loading ...
Support Center